
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
ISTA Pharmaceuticals Inc. has filed an investigational new drug application with the FDA to begin a phase III study of bromfenac.




